Search results
Biogen is buying up an immune drug developer for $1.8 billion
Quartz· 3 days agoBiotechnology giant Biogen said on Wednesday that it is acquiring immune drug developer Human...
Q1 2024 Biomx Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoIn January this year, we were granted Orphan Drug Designation by the FDA for BX004. More recently, in April, we presented positive safety and efficacy results ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoThe study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as finding effective doses in various treatment-resistant ...
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab...
FOX 23 News Albany· 2 days agoPhase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium...
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 3 days agoCartesian Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food...
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual...
Digital Journal· 3 days agoMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it ...
Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B By Investing.com
Investing.com· 7 days agoLongeveron Inc. (LGVN), a leader in regenerative medicine, recently discussed its first-quarter...
Calliditas Therapeutics stock target lifted on strong sales By Investing.com
Investing.com· 2 days agoOn Thursday, Jefferies, a global investment banking firm, raised the stock price target for...
Octapharma USA Appoints New VP of Commercial Marketing & Development
New Jersey Business Magazine· 5 days agoOctapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as vice president of...
Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid...
Morningstar· 4 days agoDELRAY BEACH, FL / ACCESSWIRE / May 21, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments ...